SCHEMBL2193875

SCHEMBL2193875

Fc1ccc(-c2nc3ccc(F)cn3c2Cn2nccn2)cc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.56
GABRB2 P47870 3/20 0.56
SLC2A1 P11166 12/20 0.51
SLC2A3 P11169 1/20 0.50
SLC2A4 P14672 1/20 0.50
SIRT5 Q9NXA8 1/20 0.46
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41
ALDH1A1 P00352 1/20 0.40
SLC2A2 P11168 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
NR1H4 Q96RI1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2195307 0.92 SLC2A3 (0.57) GABRA1GABRB2SLC2A1SLC2A3SLC2A4
SCHEMBL2198214 0.83 ALDH1A1 (0.54) SLC2A1KDM4EHTTALDH1A1POLB
SCHEMBL1432490 0.80 GABRA1 (0.51) GABRA1GABRB2SLC2A1SLC2A3SLC2A4
SCHEMBL2195258 0.80 SLC2A1 (0.66) GABRB2SLC2A1MEN1KMT2AKDM4E
Hydrochloric Acid SCHEMBL1433038 0.79 GABRA1 (0.59) GABRA1GABRB2SLC2A1SLC2A3SLC2A4
SCHEMBL2196219 0.76 SLC2A3 (0.54) GABRA1GABRB2SLC2A1SLC2A3SLC2A4
SCHEMBL2222798 0.75 SLC2A1 (0.61) GABRB2SLC2A1MEN1KMT2AKDM4E
SCHEMBL1428217 0.74 GABRA1 (0.53) GABRA1GABRB2SLC2A1SLC2A3SLC2A4
SCHEMBL1430254 0.74 GABRA1 (0.53) GABRA1GABRB2SLC2A1SLC2A3SLC2A4
SCHEMBL1432171 0.74 SLC2A3 (0.53) GABRA1GABRB2SLC2A1SLC2A3SLC2A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 US disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD GABRA1 817/4885GABRB2 1166/4885SLC2A1 2033/4885
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD GABRA1 817/4885GABRB2 1166/4885SLC2A1 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.